Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07064499

CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes

Title: CGM Boosted by Artificial Intelligence for better glycaemic control in T2 Diabetes : a real-life multicenter observational study in Belgium - MAGIC-T2D

Background: In Belgium, since May 2023, reimbursement for continuous glucose monitoring systems has been extended to people with type 2 diabetes taking multiple injections of insulin. Despite the results of previous studies, the impact of this technology in terms of glycaemic control and patient-reported outcomes (PROMs) in real life for patients with type 2 diabetes is still unclear.

Objective: To evaluate the impact of the CGMs on glycemic control and PROMs in people living with type 2 diabetes under real-life conditions.

Methods and analysis: In a multicenter real-world observational study, more than 440 people with type 2 diabetes under multiple daily injection therapy who start to be monitored by a CGM in one of the 13 participating Belgian centers, will be followed for a period of 24 months.

Outcomes: The primary and secondary endpoint are respectively the evolution of time spent in range (defined as a sensor glucose value between 70 and 180 mg/dL) and HbA1c from before start to 12 months after start of the CGM.

Exploratory objectives will be studied using artificial intelligence (AI) to study glucose profiles to characterize the heterogeneity of type 2 diabetes.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

HUB-Hôpital ERASME

Brussels, 7850, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes on MDI and starting CGM

Exclusion criteria

  • Dialysis
  • Treatment that raises blood sugar levels (corticosteroids, etc.)
  • Secondary and type 1 diabetes
  • Patient not able to sign the Informed Consent

Treatment and study plan

Primary outcomes

  1. Evolution of TIR (glucose 70-180 mg/dl) over a 12-month period after initiation of CGM in patients with T2D treated with MDI regimens.

    Time frame: From registration to end of 1-year follow-up

Secondary outcomes

  1. Evolution of Hba1c over a 12-month period after initiation of CGM

    Time frame: From registration to end of 1-year follow-up

Other outcomes

  1. Evolution of TIR according to T2D endotypes as defined by Ahlqvist et al.

    Time frame: From registration to end of 1-year follow-up

Sponsors and collaborators

Lead sponsor

Erasme University Hospital

Other

Registry information

Official study title

CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes: a Real-life Multicentre Observational Study in Belgium.

Acronym: MAGIC-T2D

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
Jul 14, 2025
Registry last updated
Aug 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.